Penumbra Inc. Reports Q2 Earnings with Strong Growth in U.S. Thrombectomy Business

Penumbra Inc. reported Q2 2025 earnings with a total revenue of $339.5 million, a 13.4% YoY increase. The U.S. thrombectomy business grew 22.6% YoY to $188.5 million, while the U.S. VTE franchise grew 42% YoY. The company raised its total revenue guidance for 2025 to a range of $1.355 billion to $1.370 billion, a 13% to 15% YoY growth. Challenges in international markets, particularly in China, and variability in operating margins due to strategic investments were noted as areas of concern.

Penumbra Inc. (NYSE: PEN) reported its second quarter 2025 earnings, showcasing a significant improvement in financial performance. The company's total revenue reached $339.5 million, marking a 13.4% year-over-year (YoY) increase. This growth was primarily driven by the robust performance of the U.S. thrombectomy business, which saw a 22.6% YoY increase to $188.5 million. Additionally, the U.S. Venous ThromboEmbolism (VTE) franchise grew by 42% YoY, contributing to the overall revenue growth [2].

The company's profitability also improved significantly. Net income for the quarter was $45.3 million, up from a $60.2 million loss in the same period last year. This turnaround was primarily due to lower expenses and a favorable product mix. The company's gross margin expanded to 66.0%, up from 54.4% in the prior year, driven by a 11.6-point increase in gross margin and the elimination of a one-time impairment charge [2].

Penumbra raised its total revenue guidance for the full year 2025 to a range of $1.355 billion to $1.370 billion, representing a 13% to 15% YoY growth. This guidance reflects the company's confidence in its core U.S. market momentum and the strategic shifts aimed at reducing operating expenses and boosting profitability [2].

However, challenges in international markets, particularly in China, and variability in operating margins due to strategic investments were noted as areas of concern. The company's international revenue decreased by 3.2% YoY, with international sales representing 23.2% of total revenue in the second quarter of 2025. Penumbra is focusing on R&D in core thrombectomy and embolization platforms while maintaining pricing discipline to outpace competitors and enhance supply chain resilience through new manufacturing facilities [2].

The company's stock surged 11.91% on July 30, 2025, following the release of the earnings report, with a trading volume of $0.30 billion, ranking 407th in market activity. The stock's rally was driven by the robust Q2 2025 earnings, which exceeded analyst estimates by $11.7 million [2].

References:
[1] https://finance.yahoo.com/news/penumbra-second-quarter-2025-earnings-105747035.html
[2] https://www.ainvest.com/news/penumbra-surges-11-9-q2-earnings-beat-margin-expansion-300m-volume-pushes-407th-trading-rank-2507/
[3] https://www.biospace.com/press-releases/penumbra-inc-reports-second-quarter-2025-financial-results